Clinical Trials for Breast Cancer: Treatment Studies and How to Enroll

—————————————————————-

Breast cancer is among the most actively researched cancers in the US, with hundreds of clinical trials enrolling at any given time across all stages, subtypes, and treatment phases. Trials cover the full spectrum from prevention and early-stage adjuvant therapy through metastatic disease, with rapid evolution in HER2-targeted, hormone-positive, and triple-negative breast cancer treatments. For patients, clinical trials for breast cancer can offer access to therapies that may not be available outside research settings, particularly for metastatic or treatment-resistant disease. This guide covers what trials are, how to find breast cancer studies, the major categories being tested, eligibility considerations, and resources for enrollment. It is educational and is not a substitute for advice from your own oncology team.

What a clinical trial is (and the phases)

A clinical trial is a carefully designed research study that tests whether a new treatment, combination, or strategy is safe and works better than what is already available. Participation is voluntary. Trials are typically described in phases:

• Phase 1 — first tests in people, focused mainly on safety, dosing, and side effects in a small group.
• Phase 2 — evaluates whether the treatment has activity against the cancer while continuing to watch safety.
• Phase 3 — compares the new approach against the current standard of care, usually in a larger, randomized group, to confirm benefit.
• Phase 4 — post-approval studies that track long-term safety and effectiveness in wider use.

Before you enroll, the research team walks you through informed consent: a plain-language explanation of the study’s purpose, procedures, potential benefits, known risks, and alternatives. Consent is an ongoing conversation, not a one-time signature — you can ask questions at any point, and you have the right to withdraw from a trial at any time, for any reason, without losing access to other care. Trials are reviewed and monitored by an Institutional Review Board (IRB) to help protect participants.

Categories of breast cancer trials

Active breast cancer trials in 2026 include:

HER2-positive breast cancer: antibody-drug conjugates (ADCs) including next-generation approaches building on trastuzumab deruxtecan (Enhertu), bispecific antibodies, and combinations of HER2-targeted therapies with other agents.

Hormone receptor-positive breast cancer: next-generation selective estrogen receptor degraders (SERDs), CDK4/6 inhibitor combinations, PI3K/AKT-pathway inhibitors, and novel endocrine therapies for treatment-resistant disease.

Triple-negative breast cancer: immunotherapy combinations, PARP inhibitors in expanded settings, antibody-drug conjugates such as sacituzumab govitecan and newer agents, and targeted therapies for specific molecular subtypes.

Early-stage adjuvant therapy: trials testing whether intensified or de-escalated regimens improve outcomes in early breast cancer.

Prevention trials: studies in high-risk people without cancer testing whether interventions can reduce the chance of developing breast cancer.

Survivorship and supportive care: trials addressing fatigue, cognitive effects, lymphedema, and quality of life for breast cancer survivors.

Where to find breast cancer trials

Reputable places to start your search:

• ClinicalTrials.gov — the comprehensive federal registry maintained by the National Library of Medicine.
• National Cancer Institute (NCI) clinical trials search — curated NCI-supported trials with patient-friendly summaries and a call center that can help you look.
• BreastCancerTrials.org — a nonprofit matching service specific to breast cancer, with detailed questionnaires.
• Susan G. Komen — research and trial resources, including a treatment assistance and clinical trial support line.
• Breastcancer.org — patient education and trial information.
• NCI-Designated Cancer Centers — major academic centers running extensive trial programs.

For metastatic breast cancer specifically, trials at NCI-Designated Comprehensive Cancer Centers often include the most innovative therapies. As of 2026 there are 74 NCI-Designated Cancer Centers, listed on the NCI website. Your oncologist and cancer center’s clinical research staff can also tell you which trials are open where you already receive care.

Subtype-specific trial considerations

Breast cancer is a heterogeneous disease, and trial eligibility usually depends on subtype:

Hormone receptor status (ER/PR): estrogen-receptor and progesterone-receptor positivity, determined by immunohistochemistry (IHC) staining.

HER2 status: HER2-positive (3+ by IHC or amplified by FISH), HER2-low (1-2+ by IHC, FISH negative), and the emerging HER2-ultralow category, versus HER2-zero.

BRCA and other mutation status: germline BRCA1/BRCA2 mutations are eligibility criteria for some trials (PARP inhibitor studies in particular).

PIK3CA/AKT pathway status: mutations in PIK3CA or related pathway genes matter for some targeted-therapy trials.

Stage: early-stage (Stages 0-III) and metastatic (Stage IV) trials have very different designs and goals.

Knowing your tumor’s complete molecular profile — standard IHC results plus any genomic testing — is essential for matching with appropriate trials. Ask your oncologist for a copy of your pathology and biomarker reports.

Typical eligibility for breast cancer trials

Common inclusion criteria:

• A confirmed breast cancer diagnosis meeting the trial’s specific subtype requirements
• Stage and treatment history matching the trial’s target population
• Adequate organ function (liver, kidney, bone marrow, cardiac)
• Performance status (often ECOG 0-2 — the ability to carry out daily activities)
• Specific lab values within defined ranges
• Adequate time since prior therapies (washout periods)

Common exclusion criteria:

• Other active malignancies
• Brain metastases (some trials exclude them; others specifically enroll this group)
• Recent chemotherapy or radiation within specific windows
• Pregnancy (almost universally excluded)
• Significant cardiac disease (especially for trials of potentially cardiotoxic drugs)
• Specific prior therapy that disqualifies (for example, a previous CDK4/6 inhibitor)

What participation involves

Breast cancer trials typically involve:

• A comprehensive baseline workup including imaging, labs, ECG, and sometimes biopsies
• Randomization in randomized trials — often to the experimental treatment versus current standard of care
• Regular treatment cycles based on the drug being tested (often every 3-4 weeks)
• Frequent imaging (typically every 6-12 weeks) to assess tumor response
• Lab monitoring for toxicity
• Quality-of-life and symptom assessments
• Long-term follow-up after treatment ends

The total time commitment varies enormously. Trials in metastatic breast cancer can continue for as long as a patient is benefiting, while adjuvant trials often have defined treatment durations of 6-12 months followed by years of follow-up. Ask the research team what is covered by the study and what your insurance is expected to cover; routine care costs are usually billed as usual, while research-specific procedures are often covered by the trial.

Trials in metastatic disease

Patients with metastatic breast cancer often have a strong case for considering trial participation. Standard treatments may have stopped working or may carry significant toxicity, and trials can offer access to newer approaches such as:

• Antibody-drug conjugates targeting HER2, TROP2, and other markers
• Bispecific antibodies engaging more than one immune mechanism
• Novel hormone-receptor-targeting agents
• Combinations of immunotherapy with other therapies
• Targeted therapies for specific molecular subtypes

For metastatic disease, comprehensive genomic testing of the tumor (or of circulating tumor DNA) is often useful to identify trial-eligible mutations. Many academic centers offer this testing as part of routine care. A trial may or may not help any individual — it is research, and benefit is never guaranteed — but for many patients it meaningfully expands the options worth discussing.

Adjuvant and neoadjuvant trials

Trials in early-stage breast cancer test whether adding, intensifying, or de-escalating treatment improves outcomes. Examples include:

• Adjuvant CDK4/6 inhibitors (such as abemaciclib, whose adjuvant use was established by the monarchE trial)
• Adjuvant olaparib for BRCA-mutated breast cancer
• De-escalation trials testing whether less treatment is equally effective with fewer side effects
• Neoadjuvant immunotherapy trials in triple-negative disease

These trials often involve large numbers of patients (1,000+) and long follow-up to assess outcomes such as disease-free survival.

Prevention trials and the role of screening

People at high risk of breast cancer (strong family history, BRCA mutations, or prior atypical hyperplasia) can participate in prevention trials testing whether interventions reduce cancer development. Examples include:

• Anti-estrogen therapies in high-risk individuals (tamoxifen, raloxifene, aromatase inhibitors)
• Vaccine trials targeting molecular changes in pre-cancerous breast tissue
• Lifestyle-intervention trials (exercise, diet, weight management)

The Breast Cancer Research Foundation and the National Cancer Institute support extensive prevention research. Prevention starts with screening, too: in its 2024 update, the U.S. Preventive Services Task Force now recommends that women at average risk begin screening mammography at age 40 and continue every other year through age 74. The American Cancer Society offers the option to start annual screening at 40 and recommends annual mammograms for ages 45-54. Talk with your clinician about the schedule that fits your personal risk.

Frequently Asked Questions

Are breast cancer trials only for patients without other treatment options?

No. This is a common misconception. Trials enroll across all stages and treatment lines. Some are specifically for patients starting first-line treatment; others target patients whose disease has progressed on standard therapies. Trials for early-stage disease often run alongside standard treatment rather than replacing it.

Will I get the standard of care if I’m in a trial?

Most modern breast cancer trials use active comparators rather than a placebo alone — meaning you generally receive either the experimental treatment or the current standard of care. Pure placebo controls are uncommon and are typically used only when there is no established standard treatment for that situation. The consent form spells out exactly what each study arm involves.

How important is the cancer subtype for trial matching?

Very important. Most trials are subtype-specific. HER2-positive, hormone-positive, and triple-negative trials are largely separate. Knowing your complete tumor molecular profile is essential for finding studies you may be eligible for.

Can I participate in a trial at one hospital while getting standard care elsewhere?

Sometimes. Some trials allow this; others require care at the trial site for safety monitoring. The protocol specifies the requirements. Coordinate carefully with both teams to avoid duplicate treatments or gaps in care.

What if I want to leave the trial, or I have brain metastases?

You can withdraw from a trial at any time without penalty and return to standard care. As for brain metastases, some trials exclude patients who have them, while others specifically enroll this population — brain metastases are a particular concern in HER2-positive disease, and dedicated CNS-metastasis trials exist. Importantly, do not stop your current treatment to pursue a trial without first talking to your oncologist.

The bottom line on breast cancer trials

Breast cancer is among the most actively researched cancers, with hundreds of active trials covering every subtype and stage. For patients with metastatic or treatment-resistant disease, trials can offer access to newer therapies before broad approval — though a trial is research, and results are never guaranteed. Subtype-specific matching matters, so know your tumor’s molecular profile. NCI-Designated Cancer Centers and major academic medical centers run the most extensive trial programs. Discuss trial options with your oncologist as part of comprehensive treatment planning, and do not change your current treatment on your own to enroll. For many patients with good performance status and adequate organ function, trial participation expands rather than replaces standard care.

Sources

• ClinicalTrials.gov — U.S. National Library of Medicine (NIH)
• National Cancer Institute (NCI) — Clinical Trials Information and NCI-Designated Cancer Centers
• U.S. Preventive Services Task Force — Breast Cancer: Screening (2024 recommendation)
• American Cancer Society — Breast Cancer Screening Guidelines
• BreastCancerTrials.org — nonprofit breast cancer trial matching service